Ascendis Pharma A/S (A71.SG)
| Previous close | 130.00 |
| Open | 129.00 |
| Bid | 130.00 x 0 |
| Ask | 135.00 x 0 |
| Day's range | 129.00 - 129.00 |
| 52-week range | 63.00 - 145.00 |
| Volume | |
| Avg. volume | 26 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 25 Apr 2024 - 29 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireAscendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024
COPENHAGEN, Denmark, March 04, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Leerink Partners Global Biopharma Conference 2024 on Monday, March 11, 2024 at 2:00 p.m. ET in Miami, Florida. A live webcast of the fireside chat will be available via the Investors & News section of the Ascendis Pharma website at investors.ascendispharma.com. A webcast replay will also be available on this website shortly
- GlobeNewswire
Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results
Launch of TransCon™ PTH underway with full commercial availability in Germany and Austria; U.S. PDUFA date of May 14, 2024TransCon CNP pivotal ApproaCH Trial on track for topline results in Q4 2024Total Q4 revenue of €138 million including SKYTROFA® revenue of €64 million; Q4 operating expenses of €155 million Conference call today at 4:30 pm ET COPENHAGEN, Denmark, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the fourth quarter and f
- GlobeNewswire
Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
COPENHAGEN, Denmark, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference. Details: EventOppenheimer 34th Annual Healthcare Life Sciences ConferenceLocationVirtualDateTuesday, February 13, 2024Time4:00 p.m. Eastern Time / 1:00 p.m. Pacific Time A live webcast of the event will be available via the Investors & News section of the Ascendis Pharma website at in
